3 results
Approved WMOPending
Phase 1 - Primary Objective• To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of single-agent MCLA-129 in patients with NSCLC, GC/GEJ adenocarcinoma, HNSCC or ESCC, with disease progression after prior therapy for…
Approved WMOPending
The objective of this study is to achieve better adherence to fluid restriction by providing insight to patient*s drinking behavior, by using the MySleeve device (MS).
Approved WMORecruiting
The purpose of this trial is to determine the safety and efficacy of TAVR via a transfemoral approach in HF patients with moderate AS as compared with OHFT with regard to the composite of death, stroke, hospital admissions, symptoms, functional…